NasdaqCM - Nasdaq Real Time Price USD

VYNE Therapeutics Inc. (VYNE)

Compare
3.4300
-0.4900
(-12.50%)
At close: January 10 at 4:00:01 PM EST
3.4300
0.00
(0.00%)
After hours: January 10 at 7:33:03 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
493.0000
424.0000
477.0000
931.0000
20,993.0000
Cost of Revenue
--
--
--
3,348.0000
1,392.0000
Gross Profit
--
--
--
11,407.0000
19,601.0000
Operating Expense
38,192.0000
29,682.0000
34,772.0000
39,842.0000
133,076.0000
Operating Income
-37,699.0000
-29,258.0000
-34,295.0000
-38,911.0000
-113,475.0000
Net Non Operating Interest Income Expense
--
--
--
-5,610.0000
-4,390.0000
Other Income Expense
3,754.0000
1,386.0000
363.0000
-135.0000
-137,961.0000
Pretax Income
-33,945.0000
-27,872.0000
-33,932.0000
-44,656.0000
-255,826.0000
Tax Provision
--
--
13.0000
-448.0000
-258.0000
Net Income Common Stockholders
-34,000.0000
-28,452.0000
-23,210.0000
-73,329.0000
-255,568.0000
Diluted NI Available to Com Stockholders
-34,000.0000
-28,452.0000
-23,210.0000
-73,329.0000
-255,568.0000
Basic EPS
3.39
-2.78
-7.28
-25.56
-141.84
Diluted EPS
3.39
-2.78
-7.28
-25.56
-141.84
Basic Average Shares
39,763.7500
10,273.0000
3,186.0000
2,859.3880
1,801.0000
Diluted Average Shares
39,763.7500
10,273.0000
3,186.0000
2,859.3880
1,801.0000
Total Operating Income as Reported
-37,699.0000
-29,258.0000
-34,295.0000
-38,911.0000
252,546.0000
Total Expenses
38,192.0000
29,682.0000
34,772.0000
39,842.0000
134,468.0000
Net Income from Continuing & Discontinued Operation
-34,000.0000
-28,452.0000
-23,210.0000
-73,329.0000
-255,568.0000
Normalized Income
-33,945.0000
-27,872.0000
-33,945.0000
-44,208.0000
-116,636.0710
Interest Expense
--
--
--
5,610.0000
4,390.0000
Net Interest Income
--
--
--
-5,610.0000
-4,390.0000
EBIT
-37,699.0000
-29,258.0000
-34,295.0000
-39,046.0000
-251,436.0000
EBITDA
-37,699.0000
-29,258.0000
-34,223.0000
-38,937.0000
-251,095.0000
Reconciled Cost of Revenue
--
--
--
3,348.0000
1,392.0000
Reconciled Depreciation
--
--
72.0000
109.0000
341.0000
Net Income from Continuing Operation Net Minority Interest
-33,945.0000
-27,872.0000
-33,945.0000
-44,208.0000
-255,568.0000
Total Unusual Items Excluding Goodwill
--
--
--
--
-139,071.0000
Total Unusual Items
--
--
--
--
-139,071.0000
Normalized EBITDA
-37,699.0000
-29,258.0000
-34,223.0000
-38,937.0000
-112,024.0000
Tax Rate for Calcs
--
--
0.0002
0.0000
0.0000
Tax Effect of Unusual Items
--
--
--
--
-139.0710
12/31/2020 - 1/25/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

STOK Stoke Therapeutics, Inc.
9.00
+0.45%
 
RZLT Rezolute, Inc.
4.9000
-5.95%
 
LSTA Lisata Therapeutics, Inc.
3.7300
-1.84%
 
TRVI Trevi Therapeutics, Inc.
3.8200
-5.21%
 
VRDN Viridian Therapeutics, Inc.
18.20
-4.96%
 
OCS Oculis Holding AG
21.15
+13.10%
 
MRSN Mersana Therapeutics, Inc.
0.7200
-44.62%
 
GHRS GH Research PLC
8.57
-4.57%
 
CGEM Cullinan Therapeutics, Inc.
11.19
+0.54%
 
CLDX Celldex Therapeutics, Inc.
24.35
-8.22%